Lytix Biopharma – Invitation to Capital Markets Day in Oslo, June 1, 2022
Intratumoral treatment of Basal Cell Carcinoma (BCC) – first-in-class cancer therapyThe CMD is a live event, open for physical attendance at Hotel Continental in Oslo, Norway, as well as a live webcast. It starts at 14.00 CET, and is expected to last approximately two hours, including Q&A. Speakers will be: · Øystein Rekdal, CEO of Lytix · The core of Lytix' Biopharma's technology platform; eradiction of solid tumors · Ted White, CEO of Verrica Pharmaceuticals Inc. · Why we partnered with Lytix to pursue the commercial opportunity for LTX-315 in BCC and SCC